8th Feb 2016 07:00
Notice of Results
LONDON, UK, 8 February, 2016 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug development company, plans to announce its annual financial results for the year ended 31 December 2015 on Wednesday 16 March 2016. The results presentation and a webcast recording of the event will be available on the Company's website at www.skyepharma.com.
-Ends-
For further information, please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer Andrew Derodra, Chief Financial Officer | +44 207 881 0524 |
Jonathan Birt, Investor and Media Relations
| +44 786 036 1746 |
FTI Consulting | |
Julia Phillips/Rob Winder/Natalie Garland-Collins
| +44 203 727 1000 |
N+1 Singer | |
Shaun Dobson/Gillian Martin/Jen Boorer | +44 207 496 3000 |
About Skyepharma
Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 16 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies. For more information, visit www.skyepharma.com
Related Shares:
SKP.L